Regeneron (1REGN) Stock Price & Analysis
1REGN Stock Chart & Stats
- Day’s Range
- EUR 819.20 - EUR 860.90
- 52-Week Range
- EUR 495.00 - EUR 1,009.00
- Previous Close
- EUR 818.60
- Volume
- N/A
- Average Volume (3M)
- 8
- Market Cap
- EUR 85.40B
- Enterprise Value
- EUR 73.47B
- Total Cash (Recent Filing)
- EUR 9.30B
- Total Debt (Recent Filing)
- EUR 2.71B
- Price to Earnings (P/E)
- 20.5
- Beta
- 0.44
- Next Earnings
- Jan 29, 2027 (Est.)
- EPS Estimate
- 22.7
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.37%
Bulls Say, Bears Say
Bulls Say
Dupixent Growth
Dupixent combines rapid sales growth with broad adoption across nine inflammatory diseases and more than 1.5 million patients. This scale supports durable commercial momentum, strengthens Regeneron’s collaboration economics with Sanofi, and provides a substantial foundation for ongoing investment.
Expanded Sanofi Alliance
The expanded Sanofi relationship broadens Regeneron’s immunology pipeline while sharing development costs and global commercial risk. Regeneron retains lead development and U.S. regulatory roles, preserving strategic influence as new long-acting and bispecific therapies advance.
Balance Sheet And Cash Generation
Very low leverage and substantial recurring cash generation give Regeneron flexibility to fund research, business development, shareholder returns, and commercialization without relying heavily on external financing. This financial resilience supports execution through pipeline investment cycles.
Bears Say
EYLEA Franchise Pressure
EYLEA remains an important product franchise, but falling U.S. demand and increasing biosimilar competition create a durable headwind to revenue and pricing. EYLEA HD growth may partly offset erosion, yet ongoing substitution pressure could constrain portfolio-level expansion.
Margin Normalization
Regeneron remains highly profitable, but margins have normalized materially from earlier peaks. Lower profitability than prior years may limit operating leverage and reduce the earnings benefit from revenue growth, particularly as investment and commercial pressures increase.
Higher Investment And Tax Burden
A sharp increase in R&D spending reflects ambitious pipeline expansion but can pressure near-term operating margins before new products contribute revenue. A higher effective tax rate would further reduce earnings conversion, increasing execution demands across development programs.
Regeneron News
1REGN FAQ
What was Regeneron’s price range in the past 12 months?
What is Regeneron’s market cap?
When is Regeneron’s upcoming earnings report date?
How were Regeneron’s earnings last quarter?
Is Regeneron overvalued?
Does Regeneron pay dividends?
What is Regeneron’s EPS estimate?
How many shares outstanding does Regeneron have?
What happened to Regeneron’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Regeneron?
What is the TipRanks Smart Score and how is it calculated?
Regeneron Stock Smart Score
Company Description
Regeneron
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Leonard S. Schleifer
- Employees
- 15,410
- Website
- www.regeneron.com
- Address
- 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6707, US
Regeneron (1REGN) Earnings & Revenues
1REGN Company Deck
1REGN Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, supported by 36% revenue growth, 70% earnings-per-share growth, record sales for Dupixent, EYLEA HD, and Libtayo, strong cash generation, an expanded Sanofi alliance, and substantial progress across a broad clinical pipeline. The principal challenges were declining EYLEA sales and demand, biosimilar and pricing pressure, modest lynozyfic growth in its current setting, a higher expected tax rate, and no anticipated Inmazeb revenue in the fourth quarter of 2026. Highlights significantly outweighed the lowlights.
View all IT:1REGN earnings summaries1REGN Net sales Breakdown
- 43.99% Net product sales
- 51.11% Collaboration revenue
- 4.90% Other revenue
1REGN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 6 |
| Technical Analysis | 3 | 1 | 6 |
| Moving Averages | 12 | 0 | 0 |
